Would you offer tarlatamab to patients with metastatic EGFR+ NSCLC that transformed into SCLC?  

Yes, in fact, we recently collaborated on a multi-institutional report of a small cohort of such patients and have tried it a few additional times since then for patients with EGFR (or ALK) transformed into SCLC. We have seen a few exceptional responders, suggesting there's a potential role for it, ...